QIAGEN Exceeds Outlook for Fourth Quarter and Full-Year 2022 With 14% CER Sales Growth in FY 2022 From Non-COVID Product Groups

Go back to QIAGEN Exceeds Outlook for Fourth Quarter and Full-Year 2022 With 14% CER Sales Growth in FY 2022 From Non-COVID Product Groups
Qiagen NV (NYSE: QGEN) Delayed: 50.20 +0.20 (0.40%)
Previous Close $50.00    52 Week High $28.50 
Open $50.50    52 Week Low $19.94 
Day High $50.52    P/E 173.10 
Day Low $49.90    EPS $0.29 
Volume 28,977,946       

(NYSE: QIA) Delayed: 0.00 -10.35 (100%)
Previous Close $10.35    52 Week High $ 
Open $10.35    52 Week Low $ 
Day High $10.35    P/E N/A 
Day Low $10.35    EPS $ 
Volume 0